AbbVie Inc. $ABBV Stock Purchased by Sigma Investment Counselors Inc.

Sigma Investment Counselors Inc. increased its stake in AbbVie Inc. (NYSE:ABBV) by 10.6% during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 34,537 shares of the company’s stock after buying an additional 3,299 shares during the period. Sigma Investment Counselors Inc.’s holdings in AbbVie were worth $9,034,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in the stock. Victory Financial Group LLC grew its position in AbbVie by 31.2% during the 3rd quarter. Victory Financial Group LLC now owns 11,631 shares of the company’s stock valued at $3,042,000 after purchasing an additional 2,768 shares during the last quarter. Guerra Pan Advisors LLC increased its stake in AbbVie by 2.1% during the 3rd quarter. Guerra Pan Advisors LLC now owns 3,100 shares of the company’s stock valued at $876,000 after purchasing an additional 65 shares in the last quarter. Willow Creek Wealth Management Inc. raised its holdings in AbbVie by 3.7% in the third quarter. Willow Creek Wealth Management Inc. now owns 1,480 shares of the company’s stock worth $387,000 after buying an additional 53 shares during the last quarter. Great Lakes Retirement Inc. raised its holdings in AbbVie by 5.6% in the third quarter. Great Lakes Retirement Inc. now owns 7,616 shares of the company’s stock worth $1,992,000 after buying an additional 405 shares during the last quarter. Finally, Busey Bank raised its holdings in AbbVie by 0.7% in the third quarter. Busey Bank now owns 75,203 shares of the company’s stock worth $19,672,000 after buying an additional 534 shares during the last quarter. Hedge funds and other institutional investors own 70.23% of the company’s stock.

Insider Transactions at AbbVie

In other AbbVie news, EVP Nicholas Donoghoe sold 32,710 shares of the firm’s stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $250.00, for a total value of $8,177,500.00. Following the transaction, the executive vice president directly owned 74,430 shares of the company’s stock, valued at approximately $18,607,500. This trade represents a 30.53% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 0.06% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on ABBV. Guggenheim reiterated a “buy” rating and set a $288.00 price target on shares of AbbVie in a report on Friday, October 9th. Wall Street Zen downgraded shares of AbbVie from a “strong-buy” rating to a “buy” rating in a research report on Sunday, July 5th. BNP Paribas Exane boosted their price objective on shares of AbbVie from $218.00 to $247.00 and gave the stock a “neutral” rating in a report on Tuesday, August 11th. Wolfe Research raised AbbVie from a “peer perform” rating to an “outperform” rating and upped their price objective for the company from $235.00 to $300.00 in a research report on Thursday, August 13th. Finally, Argus upped their price objective on AbbVie from $250.00 to $270.00 in a research report on Tuesday, August 4th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and six have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $279.86.

AbbVie Price Performance

NYSE ABBV opened at $286.70 on Wednesday. The business’s fifty day moving average price is $267.66 and its 200-day moving average price is $236.20. AbbVie Inc. has a 1-year low of $190.75 and a 1-year high of $291.40.

AbbVie (NYSE:ABBV) last released its quarterly earnings results on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.61 by $0.04. The firm had revenue of $16.99 billion during the quarter, compared to analysts’ expectations of $16.80 billion. During the same quarter last year, the business earned $2.97 earnings per share. The business’s quarterly revenue was up 10.2% on a year-over-year basis. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Research analysts anticipate that AbbVie Inc. will post 13.92 EPS for the current fiscal year.

AbbVie Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, November 16th. Shareholders of record on Thursday, October 15th will be issued a $1.73 dividend. The ex-dividend date of this dividend is Thursday, October 15th. This represents a $6.92 dividend on an annualized basis and a yield of 2.4%.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie submitted a biologics license application to the FDA for etentamig, a next-generation BCMA×CD3 bispecific antibody for adults with relapsed or refractory multiple myeloma. In the Phase 3 CERVINO study, the treatment significantly improved overall response rate and progression-free survival versus available standard therapies, supporting potential pipeline diversification beyond immunology. AbbVie Submits BLA for Etentamig
• Positive Sentiment: The FDA approved a subcutaneous induction regimen for SKYRIZI in Crohn’s disease, including an on-body injector that enables an at-home treatment start. The approval could improve patient convenience and help support continued growth of AbbVie’s key immunology franchise. FDA Approves SKYRIZI Crohn’s Disease Regimen
• Positive Sentiment: Goldman Sachs raised its AbbVie price target to $294, while reports that Citadel has built an approximately $900 million position may reinforce institutional confidence. Analysts also identify SKYRIZI and RINVOQ as important growth drivers.
• Neutral Sentiment: Options markets imply an approximately 5% potential move around the October 30 earnings release. AbbVie previously exceeded quarterly EPS and revenue expectations, but investors will focus on SKYRIZI and RINVOQ sales, expenses and updated guidance.
• Negative Sentiment: Some analysts view ABBV as fully valued after its strong run, with rising expenses, declining estimates and intensifying competition creating near-term risks. Erste Group Bank also reduced its EPS forecast, potentially limiting upside ahead of earnings.

About AbbVie

AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.

The company’s key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.